Partnering Strategies for Accelerating Development and Improving Patient Access in Asia

In Market Access, Orphan Drugs Live by rachel

orphan big 1 a


Earlier this year at the World Orphan Drug Congress Asia 2013 Oved Amitay, Vice President, Head of Commercial , Alnylam Pharamceutical delivered the presentation: Successful partnering strategies for accelerating development and improving patient access in Asia.

The contents of this presentation is as follows:

  • Alnylam is creating a new class of high impact therapies, using powerful and natural mechanism known as RNAi, to significantly improve the lives of patients
  • Development strategy focuses on genetically defined target/disease
  • Commercialization strategy to maximize value centers on high unmet need indications, concentrated market access and strong patient advocacy
  • Strategy for lead programs is to commercialize directly in North America, South America and Europe
  • »TTR-mediated amyloidosis, hemophilia, and porphyria (AIP)
  • Selectively partner in Asian markets to accelerate development and improve patient access to transformative therapies


Click here to download this presentation


If this interests you then you may also be interested in attending the World Orphan Drug Congress Asia 2014, taking place in Singapore in June. Click here to visit the event website